EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

Most KRAS G12C mutant non-small cell lung cancer (NSCLC) patients experience clinical benefit from selective KRAS G12C inhibition, while patients with colorectal cancer (CRC) bearing the same mutation rarely respond. To investigate the cause of the limited efficacy of KRAS G12C inhibitors in CRC, we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Discov
Hauptverfasser: Amodio, Vito, Yaeger, Rona, Arcella, Pamela, Cancelliere, Carlotta, Lamba, Simona, Lorenzato, Annalisa, Arena, Sabrina, Montone, Monica, Mussolin, Benedetta, Bian, Yu, Whaley, Adele, Pinnelli, Marika, Murciano-Goroff, Yonina R., Vakiani, Efsevia, Valeri, Nicola, Liao, Wei-Li, Bhalkikar, Anuja, Thyparambil, Sheeno, Zhao, Hui-Yong, De Stanchina, Elisa, Marsoni, Silvia, Siena, Salvatore, Bertotti, Andrea, Trusolino, Livio, Li, Bob T., Rosen, Neal, Di Nicolantonio, Federica, Bardelli, Alberto, Misale, Sandra
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7416460/
https://ncbi.nlm.nih.gov/pubmed/32430388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-0187
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge